Best Immunotherapy Companies in Australia
The 46 best Immunotherapy companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Aravax.
- ResearchAndMarkets.com
- The Business Research Company
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Australia
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Aravax Developer of vaccine for peanut allergy | $93M | 30 mo ago | Series B | — | 2 | WordPressMySQLPHP+15 | — | — |
| 2 | Viralytics Developing oncolytic virotherapy treatments for a range of cancers such as Melanoma, bladder cancer. | $83M | 103 mo ago | Acquired | — | 6 | — | 59 patents Oncolytic virus-based cancer immunotherapy, especially bladder cancer treatments. | — |
| 3 | Immutep Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $66M | 61 mo ago | Acquired | Marc Voigt CEO | 35 | WordPressMySQLPHP+12 | — | — |
| 4 | ImmVirX Developer of immunotherapy for cancer treatment | $47M | 38 mo ago | Series B | Malcolm McColl Co-Founder & CEO | 16 | — | — | — |
| 5 | Immuron Developer of oral immunotherapy utilizing polyclonal antibody products | $37M | 72 mo ago | Public | Jerry Kanellos CEO | 6 | Cart FunctionalityWooCommerceWordPress+19 | 79 patents Hyperimmune bovine colostrum therapeutics for gastrointestinal and respiratory infectious diseases | 1 launch |
| 6 | OncoSil Medical Developer of a medical device for the treatment of pancreatic cancer | $28M | 14 mo ago | Public | Daniel Kenny Chief Executive Officer | 2 | WordPressMySQLPHP+28 | 7 patents Localized radiopharmaceutical delivery devices and silicon-based implants for cancer therapy | 1 partnership |
| 7 | ProTA Therapeutics Developer of oral immunotherapies for treating food allergies | $26M | 31 mo ago | Series B | Mimi Tang Founder & CEO | — | — | 16 patents Formulating and delivering allergy therapeutics, including novel pharmaceutical compositions. | — |
| 8 | Arovella Therapeutics Developer of cell therapies to treat cancer and neurological diseases | $23M | 19 mo ago | Public | — | 44 | — | 2 patents Repurposed anti‑platelet drug anagrelide for oncology, targeting thrombocytosis‑driven cancers | — |
| 9 | Chimeric Therapeutics Provider of CAR T cell therapies for solid tumors | $21M | 21 mo ago | Public | Paul Hopper Executive Chairman & Founder | 19 | WixSentryBootstrap+13 | — | 1 award |
| 10 | GPN Vaccines Developer of a vaccine against Streptococcus pneumonia | $18M | 7 mo ago | Series B | — | 24 | WordPressMySQLPHP+13 | 21 patents Streptococcal vaccine formulation and engineered immunogen technologies | — |
| 11 | BioDiem Developing and commercializing vaccine technology and infectious disease therapies. | $11M | 133 mo ago | Funding Raised | — | 5 | — | 53 patents Antifungal nitrostyrene therapeutics and radioprotective antimicrobial agents | — |
| 12 | Carina Biotech Provider of immunotherapies for the treatment of cancer | $11M | 48 mo ago | Series A | Justin Coombs Managing Director | 17 | WordPressMySQLPHP+20 | 24 patents Ovarian cancer diagnostics/therapies and CAR‑T cell immunotherapy manufacturing technologies | 1 partnership · 1 award |
| 13 | Currus Biologics Developer of CAR-T cell therapies for solid tumors | $10M | 61 mo ago | Series A | Sam Cobb CEO | 5 | — | 16 patents Engineered anti-flag and bispecific polypeptide immunotherapies to rejuvenate exhausted immune cells | 1 launch |
| 14 | Haemalogix Developer of immunotherapies for blood cancers and autoimmune diseases | $7M | 59 mo ago | Series A | — | 8 | — | 23 patents Therapeutic peptide/antibody compositions targeting myeloma antigens for cancer treatment | — |
| 15 | Paragen Bio Developer of biologics for the treatment of autoimmune diseases | $6M | 96 mo ago | Deadpooled | Norelle Daly Co-Founder | — | — | — | — |
| 16 | Ena Therapeutics Developing TLR2 angonist for the prevention of respiratory infections in the patients with preexisting lung… | $5M | 110 mo ago | Series A | Christophe Demaison CEO & Director | — | — | 29 patents TLR2 agonist immunostimulatory compounds for respiratory infections and cancer therapy | — |
| 17 | Adalta Developing next-generation antibody therapeutics for the treatment of fibrosis and cancer. | $3M | 27 mo ago | Public | — | 12 | WordPressPleskMySQL+22 | 18 patents Therapeutic biologics targeting CXCR4, RANKL, and malaria antigen binding polypeptides | 2 partnerships |
| 18 | Prescient Therapeutics Targeted small molecule inhibitors of Ras and Akt pathway for the treatment of cancer | $3M | 71 mo ago | Public | Wayne Millen CEO | 1 | WordPressMySQLPHP+28 | 16 patents Patents concentrated in health & consumer products | — |
| 19 | Imugene Developer of a therapeutic vaccine for the treatment of cancer | $2M | 19 mo ago | Public | Leslie Chong CEO & MD | 5 | WordPressMySQLPHP+23 | 15 patents Therapeutic cancer vaccines and oncolytic virus platforms delivering immune‑targeting agents | — |
| 20 | Beroni Group Developer of cell therapies for treating cancer | $2M | 34 mo ago | Public | Jacky Zhang CEO | 65 | — | — | — |
| 21 | Cyteph Developer of CAR T cell therapies for the treatment of cancer | $2M | 38 mo ago | Funding Raised | Rajiv Khanna Founder and CSO | — | — | — | — |
| 22 | Patrys Specialty company developing products for treatment of cancer | $2M | 47 mo ago | Public | James Campbell CEO and Managing Director | 23 | — | 90 patents Therapeutic antibodies targeting LM-1 antigen for cancer and metabolic applications | — |
| 23 | Implicit Bioscience Develops therapeutics for infectious diseases | $768K | 71 mo ago | Seed | Garry Redlich CEO & MD | 11 | — | 41 patents Patents concentrated in chemistry & materials | 1 partnership |
| 24 | Immune System Therapeutics Monoclonal antibodies (MAbs) to treat cancers and autoimmune diseases | $700K | 257 mo ago | Deadpooled | Rosanne Dunn Co-Founder | — | — | 18 patents Therapeutic antibodies targeting B‑cell disorders for immune disease treatment | — |
| 25 | Gamma Vaccines Australian Biotech developing broad-spectrum, intranasal vaccines against human and avian influenza virus | $552K | 200 mo ago | Seed | Tim Hirst Founder & Executive Director | — | — | 25 patents Formulation of combination vaccines using gamma‑irradiated influenza viruses and additional antigens | — |
Top 12 Immunotherapy companies in Australia
#1
Series B · Canberra, Australian Capital Territory · founded 2017 · 24 employees$18Mraised▾
Developer of a vaccine against Streptococcus pneumonia. The vaccine Gamma-PN is a whole-cell vaccine that is capable of inducing broad-spectrum T- and B-cell immunity. This is developed by using a gamma-irradiation process that inactivates and kills the vaccine strain but surface protein antigens are conserved and maintained during vaccine production that provides immunity.
- Dec 2025Series B$3.5M
- Jun 2024Series B$18M
#2
Public · Sydney, New South Wales · founded 2005 · 2 employees$27.8Mraised▾
Developer of a medical device for the treatment of pancreatic cancer. The company's flagship product includes OncoSil which is a brachytherapy device used for the treatment of pancreatic cancer. It is used to deliver beta radiation to the cancerous tissue by causing direct damage to the cancer cell DNA. The device contains proprietary diluent that acts as a carrier to implant the microparticles of radioisotope (phosphorous-32) to the targeted cell.
- May 2025Post IPO$8.7M
- Apr 2022Post IPO$10M
- Feb 2016Post IPO$7.1M
- 2005Post IPO$2M
#3
Public · Perth, Western Australia · founded 1999 · 44 employees$23Mraised▾
Developer of cell therapies to treat cancer and neurological diseases. The company is focusing on the development of a natural killer T (iNKT) cell therapy platform for the treatment of human diseases. ZolpiMist is a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. The company is developing other products to treat migraine, headaches, motion sickness, blood cancers, malignant tumors, and drug-resistant epilepsy.
- Jan 2025Post IPO$20M
- Jan 2022Post IPO$3M
#4
Public · Carlton, Victoria · founded 2020 · 19 employees$20.8Mraised▾
Provider of CAR T cell therapies for solid tumors. The company offers its proprietary clinical-stage CLTX-CART technology that includes chlorotoxin (CLTX), which is a peptide obtained from scorpion toxin, which targets the CAR-T cell in solid tumors.
- Oct 2024Post IPO$3.4M
- Jun 2023Post IPO$10.1M
- Feb 2022Post IPO$7.4M
#5
Series B · Melbourne, Victoria · founded 2015 · 2 employees$92.8Mraised▾
Developer of vaccine for peanut allergy. It offers a lead candidat PVX108 that consist of selected fragments of peanut proteins that don’t contain the parts of the nut proteins which cause the life-threatening anaphylaxis reactions and turn off their allergic reactions.
- Jan 2024Series B$22.2M
- Dec 2022Series B$20M
- May 2018Series A$1.9M
- Nov 2015Series A$4.8M
#6
Public · Armadale, Western Australia · founded 2012 · 5 employees$2.4Mraised▾
Developer of a therapeutic vaccine for the treatment of cancer. The company uses oncolytic virus and B-cell immunotherapy technology to treat a variety of cancers. Its lead product includes HER-Vaxx (HER-2 + B-cell peptide) and a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
- Dec 2024Post IPO$28.7M
- Sep 2022Post IPO$53.9M
- Nov 2019Post IPO$16.6M
- Jul 2018Post IPO$8.9M
#7
Series B · Melbourne, Victoria · founded 2017$26.5Mraised▾
Developer of oral immunotherapies for treating food allergies. The company leverages proprietary immunomodulation technology to develop immunotherapeutics targets peanut allergies in children.
- Jan 2024Series B$21M
- Jan 2024Conventional Debt—
- Jun 2017Series A$5.5M
#8
Series B · New Lambton, New South Wales · founded 2019 · 16 employees$47Mraised▾
Developer of immunotherapy for cancer treatment. It offers immuno-oncology agents based on oncolytic viruses that infect and kill cancer cells and induce systemic anti-tumor immune responses.
- Jun 2023Series B$25M
- May 2021Series B$22M
#9
Acquired · Sydney, New South Wales · founded 2001 · 35 employees$65.8Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company's product line include Eftilagimod alpha for metastatic cancers, IMP761, a humanized IgG4 monoclonal antibody for immunological diseases, and LAG525 for autoimmune diseases.
- Jun 2021Post IPO$44.9M
- Aug 2020Grant (prize money)—
- Sep 2019Post IPO$5M
- Jul 2019Post IPO$520.7K
#10
Public · Bundoora, Victoria · founded 2007 · 12 employees$3Mraised▾
AdAlta develop the next generation antibody platform, the i-body, which is a human single domain antibody like molecule. The i-body platform delivers high affinity and specific biologics against a variety of therapeutic and diagnostic targets, including, cell surface, membrane spanning and complex proteins. AdAlta is growing a pipeline of i-bodies for treatment of fibrosis and cancer utilizing the i-body technology.
- Apr 2024Post IPO$3.7M
- Dec 2021Post IPO$2.7M
- Aug 2020Post IPO$4M
- Dec 2010Series A$3M
#11
Acquired · Sydney, New South Wales · founded 2006 · 6 employees$82.7Mraised▾
Viralytics, acquired by Merck in February 2018, is focused on developing oncolytic virotherapy for the treatment of a wide range of cancers. Its lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus (RNA virus) Type A21 (CVA21). It is being evaluated in patients with Melanoma (Phase 2/3); Non-muscle invasive bladder cancer (Phase 1) and one combination study with Keytruda. CAVATAK binds to specific receptor proteins highly expressed on a range of cancer cell types, and acts to destroy local as well as metastatic tumour cells. Their lead candidate in combination with Keytruda had shown positive Phase 1b trial results in patients with late-stage melanoma.
- Jan 2018Post IPO$23.3M
- Jan 2016Post IPO$4M
- Dec 2015Post IPO$28.4M
- Jan 2014Post IPO$27M
#12
Public · Carlton, Victoria · founded 1994 · 6 employees$37Mraised▾
Developer of oral immunotherapy utilizing polyclonal antibody products. The product Travelan for traveler's diarrhea is a non-absorbable and safe product that has antibacterial antibodies that work on gut immune system and the gut microbiome and Protectyn that promote digestion and healthy gastrointestinal system health.
- Jul 2020Post IPO$20M
- Feb 2018Post IPO$5.1M
- Jun 2017Conventional Debt$1.5M
- Jul 2016Post IPO$5.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in Australia
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,119 Australia-affiliated papers.
- University College London124
- Peter MacCallum Cancer Centre95
- Monash University88
- Ludwig Cancer Research75
- The University of Sydney57
- Immune system6→89
- Cancer1→27
- Cancer immunotherapy2→25
- Tumor microenvironment3→24
- T cell2→22
- Immune system20→149
- Cancer3→53
- Oncology5→46
- Disease2→38
- Tumor microenvironment6→40
- Immune system13→63
- Disease1→38
- Cancer11→36
- Clinical trial4→22
- Oncology3→19
Where immunology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.